Cargando…

Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors

Epstein Barr Virus (EBV) infects more than 95% of the population whereupon it establishes a latent infection of B-cells that persists for life under immune control. Primary EBV infection can cause infectious mononucleosis (IM) and long-term viral carriage is associated with several malignancies and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowell, Alexander C., Haigh, Tracey A., Ryan, Gordon B., Turner, James E., Long, Heather M., Taylor, Graham S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691624/ https://www.ncbi.nlm.nih.gov/pubmed/34882759 http://dx.doi.org/10.1371/journal.ppat.1010137

Ejemplares similares

Regulation of Epstein-Barr Virus Minor Capsid Protein BORF1 by TRIM5α
por: Lin, Lih-Tsern, et al.
Publicado: (2022)

Cryo-EM structure of the EBV ribonucleotide reductase BORF2 and mechanism of APOBEC3B inhibition
por: Shaban, Nadine M., et al.
Publicado: (2022)

CXCR4 induces cell autophagy and maintains EBV latent infection in EBVaGC
por: Wang, Weiwen, et al.
Publicado: (2020)

Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity
por: Cheng, Adam Z., et al.
Publicado: (2018)

Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4(+) T Cells
por: Meckiff, Benjamin J., et al.
Publicado: (2019)

Establishment of Epstein–Barr Virus (EBV) Latent Gene-Expressing T-Cell Lines with an Expression Vector Harboring EBV Nuclear Antigen 1
por: Kanno, Hiroyuki, et al.
Publicado: (2023)

Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection
por: Lam, Janice K. P., et al.
Publicado: (2018)

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies
Publicado: (1992)

An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation
por: Pei, Yonggang, et al.
Publicado: (2017)

EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules
por: Liu, Yue, et al.
Publicado: (2023)

Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV
por: Ahmed, Naveed, et al.
Publicado: (2022)

The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8
por: Banerjee, Shuvomoy, et al.
Publicado: (2013)

An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3)
Publicado: (1990)

Unexpected Instability of Family of Repeats (FR), the Critical cis-Acting Sequence Required for EBV Latent Infection, in EBV-BAC Systems
por: Kanda, Teru, et al.
Publicado: (2011)

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens
por: Rozman, Marija, et al.
Publicado: (2022)

Overall avidity declines in TCR repertoires during latent CMV but not EBV infection
por: Couturaud, Barbara, et al.
Publicado: (2023)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar
por: Smatti, Maria K., et al.
Publicado: (2017)

Characterization of the specificity and genetic restriction of human CD4(+) cytotoxic T cell clones reactive to capsid antigen of rubella virus
por: Ou, Dawei, et al.
Publicado: (1992)

Modification of Cɛ mRNA Expression by EBV-Encoded Latent Membrane Protein 1
por: Hanashiro, Kazuhiko, et al.
Publicado: (2006)

BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV
por: Schaeffner, Marisa, et al.
Publicado: (2019)

Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL)
por: Bahri, Racha, et al.
Publicado: (2022)

CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age
por: Müller-Durovic, Bojana, et al.
Publicado: (2019)

Co-prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar
por: Gupta, Ishita, et al.
Publicado: (2020)

Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the STK39 Gene in B Cells Infected by EBV
por: Bazot, Quentin, et al.
Publicado: (2018)

CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases
por: Ruiz-Pablos, Manuel
Publicado: (2022)

Structural, Mechanistic, and Antigenic Characterization of the Human Astrovirus Capsid
por: York, Royce L., et al.
Publicado: (2016)

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
por: Zhang, Xi, et al.
Publicado: (2023)

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
por: Zhang, Chaoting, et al.
Publicado: (2021)

Correction to: Co-prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar
por: Gupta, Ishita, et al.
Publicado: (2022)

SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target
por: Emanuel, Oscar, et al.
Publicado: (2021)

Baculovirus Capsid Display Potentiates OVA Cytotoxic and Innate Immune Responses
por: Molinari, Paula, et al.
Publicado: (2011)

The impact of HLA class I and EBV latency‐II antigen‐specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma
por: Jones, K., et al.
Publicado: (2015)

CryoEM Visualization of an Adenovirus Capsid-Incorporated HIV Antigen
por: Flatt, Justin W., et al.
Publicado: (2012)

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
por: Bonifacius, Agnes, et al.
Publicado: (2023)

Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration
por: Endo, Kazuhira, et al.
Publicado: (2009)

Prognostic Significance of EBV Latent Membrane Protein 1 Expression in Lymphomas: Evidence from 15 Studies
por: Mao, Yuan, et al.
Publicado: (2013)

Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein
por: Woulfe, John, et al.
Publicado: (2016)

Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis
por: Ikeda, Masato, et al.
Publicado: (2022)

Hemin treatment drives viral reactivation and plasma cell differentiation of EBV latently infected B cells
por: Burnet, Anna M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ndird1buab5l4co0n5cvdqpusv